This photo combo created last year shows U.S. President Donald Trump (left) and Turkish President Recep Tayyip Erdogan. President Trump said Monday that he will "obliterate" Turkey's economy if Ankara does anything that in his "great and unmatched wisdom" he considers to be "off limits" in Syria. | AFP-JIJI

Business

Trump threatens to 'obliterate' Turkey's economy if it takes 'off-limits' actions in Syria

Reuters

WASHINGTON – U.S. President Donald Trump on Monday threatened to “totally destroy and obliterate” the Turkish economy if Turkey took any action he considered “off-limits” following his decision to withdraw American forces from northeastern Syria.

The withdrawal, announced by the White House late Sunday, was swiftly condemned by a bipartisan group of lawmakers over concerns that it could open the way for a Turkish strike on Kurdish-led forces long allied with Washington.

“As I have stated strongly before, and just to reiterate, if Turkey does anything that I, in my great and unmatched wisdom, consider to be off limits, I will totally destroy and obliterate the Economy of Turkey (I’ve done before!)” Trump tweeted.

GET THE BEST OF THE JAPAN TIMES
IN FIVE EASY PIECES WITH TAKE 5

JOIN THE CONVERSATION

LATEST BUSINESS STORIES

Toyota Motor Corp. President Akio Toyoda exits an e-Palette autonomous concept vehicle at the Tokyo Motor Show on Wednesday.

Tokyo Motor Show gets kid-friendly, future-oriented reboot in bid to reverse flagging attendance: The 46th Tokyo Motor Show slated to kick off Thursday will not just focus on futuristic, cutting-edge vehicles, such as self-driving cars, it will also shine a light on unconventional mobility devi...

Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix, Arizona, last year. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working.

Biogen and Eisai revive plans for Alzheimer's drug aducanumab, but prospects still shaky: Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer's treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decli...

Nikkei hits one-year high on hopes for U.S.-China trade deal: Tokyo stocks gained further ground Wednesday amid renewed hopes for progress in U.S.-China trade talks, sending the key Nikkei average to a fresh one-year high. The 225-issue Nikkei avera...